^
Association details:
| Biomarker: | FANCA mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
Excerpt:
...- Germline mutation in one or more homologous recombination DNA-repair genes (BRCA1, BRCA2, ATM, CHEK2, NBN, RAD50, RAD51C, RAD51D, PALB2, MRE11, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM) as documented by a clinical CLIA-grade, genetic test (including but...
Trial ID:
Source:
Title:
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
Excerpt:
...- Have a deleterious mutation (germline or somatic) in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B....
Trial ID:
Less C2 evidence
Source:
Title:
Preliminary Results from TRITON2: A Phase 2 Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Repair (HRR) Gene Alterations
Published date:
10/19/2019
Excerpt:
A confirmed objective response by investigator assessment was also observed in 1 patient with a BRIP1 alteration and 1 patient with a FANCA alteration (Table 2)
Trial ID:
